Insider trading

Period: 120 months Stock: ZYME + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

64 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

64 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

64 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

64 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
64 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
64 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

64 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
9 Oct 2026
Schayowitz Adam EVP, Head of R&D
Sold at will
$357.56K 13,832 at 25.85
37.3%
Not planned
12 Jan 2026
Galbraith Kenneth Chair & CEO
Sold at will
$689.82K 30,424 at 22.67
11.8%
Not planned
12 Jan 2026
Moore Paul Andrew Chief Scientific Officer
Sold at will
$216.76K 9,560 at 22.67
16.5%
Not planned
12 Jan 2026
Smith Jeffrey T L EVP & Chief Medical Officer
Sold at will
$211.09K 9,310 at 22.67
25.8%
Not planned
12 Jan 2026
Hollywood Mark EVP & Chief Operating Officer
Sold at will
$138.76K 6,120 at 22.67
4.4%
Not planned
5 Jan 2026
Galbraith Kenneth Chair & CEO
Sold at will 2×
$1.36M 54,343 at 25.10
25.6%
Not planned
5 Jan 2026
Moore Paul Andrew Chief Scientific Officer
Sold at will 2×
$504.70K 20,110 at 25.10
39.2%
Not planned
5 Jan 2026
Smith Jeffrey T L EVP & Chief Medical Officer
Sold at will
$264.47K 10,538 at 25.10
36.5%
Not planned
22 Dec 2025
Galbraith Kenneth Chair & CEO
Sold at will
$1.28M 47,528 at 27.02
26.3%
Not planned
19 May 2025
EcoR1 Capital, LLC Director · indirect
Bought
$69.74K 5,919 at 11.78
0.0%
15 May 2025
EcoR1 Capital, LLC Director · indirect
Bought
$565.85K 49,502 at 11.43
0.3%
17 Apr 2025
EcoR1 Capital, LLC Director · indirect
Bought
$630.82K 54,760 at 11.52
0.3%
16 Apr 2025
EcoR1 Capital, LLC Director · indirect
Bought
$825.59K 73,953 at 11.16
0.4%
4 Apr 2025
EcoR1 Capital, LLC Director · indirect
Bought
$2.19M 196,438 at 11.17
1.1%
3 Apr 2025
EcoR1 Capital, LLC Director · indirect
Bought
$1.43M 120,770 at 11.84
0.7%
2 Apr 2025
EcoR1 Capital, LLC Director · indirect
Bought
$881.02K 74,360 at 11.85
0.4%
1 Apr 2025
EcoR1 Capital, LLC Director · indirect
Bought
$564.65K 48,658 at 11.60
0.3%
31 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$51.66K 4,397 at 11.75
0.0%
26 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$536.86K 43,848 at 12.24
0.3%
25 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$690.45K 53,501 at 12.91
0.3%
24 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$296.85K 22,689 at 13.08
0.1%
21 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$396.52K 31,033 at 12.78
0.2%
20 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$949.88K 73,476 at 12.93
0.4%
19 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$737.23K 58,306 at 12.64
0.3%
18 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$1.44M 113,880 at 12.65
0.7%
17 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$688.46K 56,277 at 12.23
0.3%
13 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$5.85M 468,356 at 12.48
2.9%
12 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$3.59M 292,934 at 12.25
1.8%
11 Mar 2025
EcoR1 Capital, LLC Director · indirect
Bought
$3.69M 320,690 at 11.49
2.0%
17 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$274.00K 19,748 at 13.87
0.1%
16 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$1.69M 121,681 at 13.89
0.8%
15 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$546.67K 39,029 at 14.01
0.3%
14 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$739.27K 54,500 at 13.56
0.4%
13 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$992.87K 74,125 at 13.39
0.5%
10 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$2.68M 204,098 at 13.13
1.3%
8 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$295.83K 21,021 at 14.07
0.1%
6 Jan 2025
Galbraith Kenneth Chair & CEO
Sold at will 2×
$855.02K 57,291 at 14.92
54.6%
Sold half or more
6 Jan 2025
Moore Paul Andrew Chief Scientific Officer
Sold at will 2×
$316.39K 21,200 at 14.92
59.0%
Sold half or more
6 Jan 2025
Smith Jeffrey T L EVP & Chief Medical Officer
Sold at will
$165.81K 11,110 at 14.92
55.6%
Sold half or more
2 Jan 2025
EcoR1 Capital, LLC Director · indirect
Bought
$2.33M 157,880 at 14.78
1.1%
31 Dec 2024
EcoR1 Capital, LLC Director · indirect
Bought
$2.13M 146,501 at 14.57
1.0%
30 Dec 2024
EcoR1 Capital, LLC Director · indirect
Bought
$853.33K 58,988 at 14.47
0.4%
27 Dec 2024
EcoR1 Capital, LLC Director · indirect
Bought
$1.47M 101,659 at 14.49
0.7%
26 Dec 2024
EcoR1 Capital, LLC Director · indirect
Bought
$240.04K 16,692 at 14.38
0.1%
24 Dec 2024
EcoR1 Capital, LLC Director · indirect
Bought
$168.90K 11,958 at 14.12
0.1%
8 Jan 2024
Galbraith Kenneth Chair & CEO
Sold at will
$64.00K 5,706 at 11.22
19.4%
Not planned
8 Jan 2024
Moore Paul Andrew Chief Scientific Officer
Sold at will
$26.23K 2,339 at 11.22
24.1%
Not planned
8 Jan 2024
Astle Christopher SVP & Chief Financial Officer
Sold at will
$16.05K 1,431 at 11.22
18.0%
Not planned
5 Jan 2024
Galbraith Kenneth Chair & CEO
Sold at will
$193.85K 18,198 at 10.65
38.2%
Not planned
5 Jan 2024
Moore Paul Andrew Chief Scientific Officer
Sold at will
$79.47K 7,460 at 10.65
43.5%
Not planned
Showing 1–50 of 64. Page 1 of 2 Older →